Clinical Trials Logo
  1. Home
  2. SARS-CoV-2
  3. NCT04445597
  4. Details
NCT04445597 Clinical Trial

ANalyzing Olfactory Dysfunction Mechanisms In COVID-19

SARS-CoV-2 Clinical Trial

— ANOSMIC-19  

Official title:
ANalyzing Olfactory Dysfunction Mechanisms In COVID-19

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04445597
Other study ID # S64042
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 7, 2020
Est. completion date December 31, 2024

Study information
Verified date May 2023
Source Universitaire Ziekenhuizen KU Leuven
Contact Laura Van Gerven
Phone +3216336342
Email laura.vangerven@uzleuven.be
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

We aim to understand the mechanism of olfactory dysfunction in COVID-19.

Description:

In December 2019, a new coronavirus causing severe acute respiratory syndrome was described in Wuhan, China. This virus, later named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spread worldwide and has been designated a pandemic by the World Health Organization. By the beginning of March 2020, several Ear, Nose, Throat societies raised awareness of a frequent association between coronavirus disease 2019 (COVID-19) and smell disorders. In the present study, the investigators wish to begin to understand the pathogenesis of olfactory dysfunction in COVID-19.

Recruitment information / eligibility
Status Recruiting
Enrollment 150
Est. completion date December 31, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Deceased hospitalised patients, tested positive or negative for SARS-CoV-2 for patient or control group respectively Exclusion Criteria: - none

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Sampling of tissue
In all groups of participants, tissue from the nasal cavity and olfactory system will be surgically removed

Locations
Country Name City State
Belgium UZ Leuven Leuven Vlaams-Brabant

Sponsors (5)
Lead Sponsor Collaborator
Universitaire Ziekenhuizen KU Leuven AZ Sint-Jan Brugge-Oostende AV, Hospital Clinic of Barcelona, Max Planck Research Unit for Neurogenetics, Universitair Ziekenhuis Brussel

Country where clinical trial is conducted

Belgium, 

Outcome
Type Measure Description Time frame Safety issue
Primary Prevalence of SARS-CoV-2 in the sampled tissue In the sampled tissues, the investigators will determine presence of SARS-CoV-2 by means of immunohistochemistry, RNA-scope and spatial transcriptomics Immediately after death
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04527471 - Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19 Phase 2
Recruiting NCT05584202 - Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants Phase 2
Completed NCT04579549 - Repeat Testing for SARS-CoV-2 N/A
Active, not recruiting NCT05547243 - A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China N/A
Recruiting NCT04747574 - Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection Phase 1
Recruiting NCT04613310 - PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19) N/A
Terminated NCT04447404 - DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury Phase 2
Completed NCT04515147 - A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 Phase 2
Withdrawn NCT04388709 - Interferon Lambda Therapy for COVID-19 Phase 2
Active, not recruiting NCT05550142 - A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China N/A
Completed NCT04620798 - Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students N/A
Active, not recruiting NCT05547256 - A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China N/A
Completed NCT04452604 - Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19
Completed NCT04561102 - Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population
Completed NCT05366322 - A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Terminated NCT04958304 - Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
Completed NCT04690413 - NOWDx Test for the Detection of Antibodies to COVID-19 N/A